T cell-based immunotherapy for cancer: a virtual reality?

Lum, Lawrence G.

doi:10.3322/canjclin.49.2.74

Cited by 11 publications

(4 citation statements)

References 207 publications

(210 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most lung cancer patients are diagnosed at advanced stages (III or IV) and the 5‐year survival of patients with advanced NSCLC is less than 15%. Immunotherapy has recently provided an attractive alternative approach and has become the fourth treatment modality for malignant tumors, ranked after surgery, radiotherapy, and chemotherapy . At present, the main adoptive immunotherapies used in clinical trials include lymphokine‐activated killer (LAK), cytokine‐induced killer (CIK), tumor‐infiltrating lymphocytes (TIL) and tumor‐associated antigen (TAA)‐specific cytotoxic T cell (CTL).…”

mentioning

confidence: 99%

Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice

Shi

Tao

Song

et al. 2014

APMIS

View full text Add to dashboard Cite

Adoptive cell immunotherapy with cytokine-induced killer cell (CIK cell) represents a promising non-toxic anticancer therapy. However, the clinical efficacy of CIK cells is limited because of abnormal tumor vasculature. Metronomic chemotherapy shows promising anticancer activity by its potential antiangiogenic effect and reduced toxicity. We hypothesized that metronomic chemotherapy with paclitaxel could improve the antitumor effect of adoptive CIK cell immunotherapy. Mice health status was analyzed by measuring mice weight and observing mice behavior. Immunohistochemistry was used to investigate the recruitment of CIK cells, the expression of endothelial cell molecules, as well as the hypoxic tumor area. Metronomic paclitaxel synergized with adoptive CIK cell immunotherapy to inhibit the growth of non-small cell lung cancer (NSCLC). Metronomic paclitaxel reduced hypoxic tumor area and increased CIK cell infiltration. Hypoxia impeded the adhesion of CIK cells and reduced the expression of endothelial cell adhesion molecules. In vivo studies demonstrated that more CIK cells were found in endothelial cell adhesion molecules high expressed area. Our study provides a new rationale for combining metronomic chemotherapy with adoptive cell immunotherapy in the treatment of xenograft NSCLC tumors in immunodeficient mice. Further clinical trials integrating translational research are necessary to better evaluate the clinical benefit of this promising approach.

show abstract

mentioning

confidence: 99%

Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice

Shi

Tao

Song

et al. 2014

APMIS

View full text Add to dashboard Cite

show abstract

“…276,277 Several types of nanoparticles (Al 2 O 3 NPs, Fe 3 O 4 @ZnO NPs, CNTs-polymer NPs and lipid NPs) have been conjugated with antigens or loaded with cytokines to construct nanomedicines/nanovaccines, which efficiently presented tumour antigens or appropriate immune-stimulatory signals via cytokines to T-cells to elicit a potent anti-tumour immune response. [278][279][280][281][282] These nanovaccine-immunized T-cells could provide long-lasting therapeutic effects against tumours and metastases. In the case of immunotherapy, T cells are not only cell vehicles of nanomedicines but also therapeutic cells activated by nanomedicines.…”

Section: Soil-and Seed-targeted Nanomedicine Therapymentioning

confidence: 99%

Development of individualized anti-metastasis strategies by engineering nanomedicines

et al. 2015

View full text Add to dashboard Cite

Metastasis is deadly and also tough to treat as it is much more complicated than the primary tumour. Anti-metastasis approaches available so far are far from being optimal. A variety of nanomedicine formulas provide a plethora of opportunities for developing new strategies and means for tackling metastasis. It should be noted that individualized anti-metastatic nanomedicines are different from common anti-cancer nanomedicines as they specifically target different populations of malignant cells. This review briefly introduces the features of the metastatic cascade, and proposes a series of nanomedicine-based anti-metastasis strategies aiming to block each metastatic step. Moreover, we also concisely introduce the advantages of several promising nanoparticle platforms and their potential for constructing state-of-the-art individualized anti-metastatic nanomedicines.

show abstract

“…Immunotherapy represents one of the most promising cancer therapeutic strategies in this arena . The immune cells, specifically CTLs, play a vital role in an effective antitumor immune response . In prevailing immunotherapy treatments, the bispecific antibody therapeutic strategy has been shown to effectively engage and activate T cells by binding CD3 molecules and tumor antigens on the surface of target tumor cells.…”

mentioning

confidence: 99%

“…(6) The immune cells, specifically CTLs, play a vital role in an effective antitumor immune response. (7)(8)(9) In prevailing immunotherapy treatments, the bispecific antibody therapeutic strategy has been shown to effectively engage and activate T cells by binding CD3 molecules and tumor antigens on the surface of target tumor cells. Novel Bispecific T-cell Engager (BiTE; Micromet, Munich, Germany) antibodies are designed to transiently connect T cells with cancer cells for initiation of redirected target cell lysis.…”

mentioning

confidence: 99%

Immunotherapy based on bispecific T‐cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma

Zou

Chen

Zong³

et al. 2015

Cancer Science

View full text Add to dashboard Cite

Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug, OKT3 (muromonab-CD3), showed great performance in clinical treatment. We have successfully developed a single-chain variable fragment (ScFv) combination of anti-CD3 ScFv and anti-CD138 ScFv with the hIgG1 Fc (hIgFc) sequence. The novel bispecific T-cell engager (BiTE) with an additional hIgFc (BiTE-hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells (RPMI-8226 or U266). In addition, BiTE-hIgFc (STL001) has nanomolar-level affinity to recombinant human CD138 protein and shows more potent antitumor activity against RPMI-8226 cells than that of separate aCD3-ScFv-hIgFc and aCD138-ScFv-hIgFc, or the isotype mAb in vitro or in vivo.

show abstract

T cell-based immunotherapy for cancer: a virtual reality?

Cited by 11 publications

References 207 publications

Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice

Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice

Development of individualized anti-metastasis strategies by engineering nanomedicines

Immunotherapy based on bispecific T‐cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma

Contact Info

Product

Resources

About